

Product Data Sheet

Product Name: NSC745885

Cat. No.: GC61142

Chemical Properties

Cas. No. 4219-52-7

SMILES O=C(C1=C(C2=O)C3=NSN=C3C=C1)C4=C2C=CC=C4

Formula $C_{14}H_6N_2O_2S$ M.Wt 266.27


Solubility DMSO: < 1 mg/mL (insoluble or slightly soluble) *NSC745885 is usually formulated as a suspension.

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

NSC745885 is an effective anti-tumor agent, showing selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

NSC745885 (0.5-4 μ M; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC₅₀ of NSC745885 is 0.85 μ M after 72 hours' treatment[1]. NSC745885 (0.5-4 μ M; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner[1]. NSC745885 (0.5-2 μ M; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells[1]. Cell Viability Assay[1] Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin[1]. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice[1]

[1]. Chen YW, et al. A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo. PLoS One. 2014 Aug 15;9(8):e104703. [2]. Tang SH, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. Oncotarget. 2014 Nov 15;5(21):10342-55.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA